Translate
Ronny Allan
August 25, 2022 — A new gallium-68 PET radiotracer appears effective for predicting higher risk of disease progression and mortality in patients with neuroendocrine tumors, according to a study published August 18 in the Journal of Nuclear Medicine.
Conclusion: Tumor lesion uptake of 68Ga-NODAGA-E[c(RGDyK)]2 was evident in patients with all grades of NEN. High uptake was associated with a poorer prognosis. Further studies are warranted to establish if 68Ga-NODAGA-E[c(RGDyK)]2 PET/CT may become a prediction tool for identification of patients eligible for treatments targeting integrin αvβ3.
Why is this different to regular Ga68 Dotatate?
In the simplest of terms, Ga68 Dotatate is targeting somatostatin receptors which are known to be expressed by most NETs, it can help indicate if treatment using somatostatin analogue therapy is feasible. Integrin αvβ3 recognizing cell surface integrins is upregulated on endothelial cells during angiogenesis and on tumor cells. Due to its involvement in tumor growth, invasiveness/metastases, and angiogenesis, integrin αvβ3 is an attractive target in cancers. It could therefore become a prediction tool for the identification of patients eligible for treatments targeting integrin αvβ3.
However, Ga68 Dotatate really only confirms that a NET may be present, particularly when uptake is intense. Ga68 NODAGA-E[c(RGDyK)]2 may be associated with prognosis when uptake is high, and this could influence therapeutic choices and approach.
The study abstract (click on the link below)
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Subscribe to my newsletter
Top 10 Posts & Pages in the last 48 hours (auto updates) (Click the titles to read them)
Thanks for reading.
I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’
Sign up for my newsletters – Click Here
My Diagnosis and Treatment History
Check out my online presentations
Check out my WEGO Health Awards
Like my new awareness page – click here or on the photo. (Like rather than follow please!)
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
RonnyAllan.NET – Summary of January 2023 – Ronny Allan – Living with Neuroendocrine Cancer
SummaryGreat start to 2023 and I thank those who continue to support my social media and this blog. I’m keen to hear any suggestions of
Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies (incl NET)
Trial Summary This interesting trial is a multi-cancer effort including NET. The phase I clinical trial of Procaspase Activating Compound-1 (PAC-1), a drug that spurs
Dustin Diamond
I’m behind the curve on this one after being ahead on celebrities such as Steve Jobs, Aretha Franklin, Wilko Johnson and Olivia Williams. But in
Neuroendocrine tumors are uncommon but definitely not rare
USA finally commits UK and Australian figures recently confirmed that Neuroendocrine Cancer is the 10th and 7th most common cancer type. It was great to
Cancer Ablation
What is Cancer Ablation? This is a minimally invasive surgical method to treat solid cancers. Special probes are used to “burn” or “freeze” cancers. Computed
Lactose intolerance – the NET Effect
Background When I cast my mind back to my very first surgery, I remember asking my Oncologist what I could do to put on weight.
EUS Guided Ablation for small pancreatic NETs (Less than 2cm)
To burn or not to burn? I once wrote a post about Pancreatic NET “to cut or not to cut”. You can read that here.
RonnyAllan.NET – a review of 2022
Review In 2022, my pet project (my blog) hit 2 million views in early November – that was a major boost. It takes 3-4 years to get
RonnyAllan.NET – Summary of December 2022
Summary December is always the quietest month of the year, no surprise why! However, the top 10 below is somewhat surprising, I guess some posts
